Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Übersichtsarbeit

Antipsychotika-induzierte tardive Bewegungsstörungen – Fallbeispiel einer tardiven Dystonie unter Aripiprazol und Literaturübersicht

Published Online:September 26, 2016https://doi.org/10.1024/1422-4917/a000460

Abstract

Zusammenfassung. Extrapyramidalmotorische Nebenwirkungen (EPMS) werden im Vergleich zu Antipsychotika der ersten Generation (FGA) unter Antipsychotika der zweiten Generation (SGA) seltener beschrieben. Dies scheint bei Erwachsenen auch tardive Dyskinesien (TDs) einzuschließen, jedoch nicht tardive Dystonien (TDts). Bei Kindern und Jugendlichen wurde unter FGA eine TD seltener beobachtet als bei Erwachsenen. Zur TDt existieren keine Daten. Unter SGA finden sich zu tardiven Bewegungsstörungen bei Kindern und Jugendlichen nur wenige und widersprüchliche Angaben. SGA unterscheiden sich in ihrem Nebenwirkungsprofil. Dabei verursacht Aripiprazol zwar weniger metabolische und kardiale Nebenwirkungen, verglichen mit anderen SGA bei Kindern und Jugendlichen jedoch relativ häufig EPMS. Bisher wurden TDs oder TDts unter Aripiprazol nur bei Erwachsenen beschrieben. Anhand des Fallberichts einer TDt unter Aripiprazol bei einer 13-jährigen Patientin werden Symptomatik, Differentialdiagnostik, Pathophysiologie, Prävalenz und Therapie tardiver Dystonien dargestellt. Unter Medikation mit SGA sollte das mögliche Auftreten von EPMS einschließlich tardiver Bewegungsstörungen berücksichtigt und klinisch regelmäßig überprüft werden.


Tardive movement disorders with antipsychotics – a case of aripirazole-induced tardive dystonia and review of the literature

Abstract. Extrapyramidal adverse events (EPS) occur less frequently with second-generation antipsychotics (SGAs) than with first-generation antipsychotics (FGAs). Tardive dyskinesia (TD), but not tardive dystonia (TDt), also seems to occur less often in adults. TD was found to occur less frequently in children and adolescents treated with FGAs than in adults. No data are available on TDt, and the data pertaining to SGAs are limited and conflicting. SGAs differ in their profile of adverse events. Aripiprazole is less frequently associated with adverse metabolic or cardiac events, but more often with EPS, at least in children and adolescents. To date, there are several case reports of TD or TDt with aripiprazole in adults. Symptomatology, differential diagnosis, pathophysiology, prevalence, and therapy of TDt are presented here based on a case report of TDt during aripiprazole therapy in a 13-year-old girl. During medication with SGAs, the occurrence of EPS, including tardive movement disorders, should be considered and regularly monitored.

Literatur

  • Albanese, A., Bhatia, K., Bressman, S. B., DeLong, M. R., Fahn, S. & Fung, V. S. C., et al. (2013). Phenomenology and classification of dystonia: a consensus update. Movement Disorders, 28, 863–873. First citation in articleCrossref Medline, Google Scholar

  • Bachmann, C. J., Lempp, T., Glaeske, G. & Hoffmann, F. (2014). Antipsychotika-Verordnungen bei Kindern und Jugendlichen. Deutsches Ärzteblatt, 111, 25–34. First citation in articleGoogle Scholar

  • Balhara, J. P. S., Chawla, J. M. & Sagar, R. (2009). Olanzapine induced tardive dystonia in case of adolescent bipolar disorder. Journal of Pediatric Neurosciences, 4, 30–32. First citation in articleCrossref Medline, Google Scholar

  • Barnes, T. (1989). A rating scale for drug-induced akathisia. The British Journal of Psychiatry, 154, 672–676. First citation in articleCrossref Medline, Google Scholar

  • Brown, H. E., Flaherty, A. W., Goff, D. C. & Freudenreich, O. (2011). A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole. Primary Care Companion for CNS Disorders, 13(6), PCC.11l01188. First citation in articleGoogle Scholar

  • Burke, R. E., Fahn, S., Jankovic, J., Marsden, C. D., Lang, A. E. & Gollomp, S., et al. (1982). Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology, 32, 1335–1345. First citation in articleCrossref Medline, Google Scholar

  • Carbon, M., Kapoor, S., Sheridan, E., Al-Jadiri, A., Azzo, S. & Sarkaria, T., et al. (2015). Neuromotor adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 second-generation antipsychotics. Journal of the American Academy of Child and Adolescent Psychiatry, 54, 718–727. First citation in articleCrossref Medline, Google Scholar

  • Carrey, N. (2009). Developmental neurobiology: Implications for pediatric psychopharmacology. The Canadian Journal of Psychiatry, 46, 810–818. First citation in articleGoogle Scholar

  • Charfi, F., Cohen, D., Houeto, J.-L., Soubrié, C. & Mazet, P. (2004). Tardive dystonia induced by atypical neuroleptics: a case report with olanzapine. Journal of Child and Adolescent Psychopharmacology, 14, 149–152. First citation in articleCrossref Medline, Google Scholar

  • Cohen, P., Bonnot, O., Bodeau, N., Consoli, A. & Laurent, C. (2012). Adverse effects of second-generation antipsychotics in children and adolescents. Journal of Clinical Psychopharmacology, 32, 309–316. First citation in articleCrossref Medline, Google Scholar

  • Connor, D. F., Fletcher, K. E. & Wood, J. S. (2001). Neuroleptic-related dyskinesias in children and adolescents. Journal of Clinical Psychiatry, 62, 967–974. First citation in articleCrossref Medline, Google Scholar

  • Correll, C. U. & Kane, J. M. (2007). One-year incidence rates of tardive dyskinesias in children and adolescents treated with second-generation antipsychotics: a systematic review. Journal of Child and Adolescent Psychopharmacology, 17, 647–656. First citation in articleCrossref Medline, Google Scholar

  • Correll, C. U., Leucht, S. & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry, 161, 414–425. First citation in articleCrossref Medline, Google Scholar

  • Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N. & Ivanova, S., et al. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry, 165, 1432–1441. First citation in articleCrossref Medline, Google Scholar

  • Findling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R.D. & Jin, N., et al. (2013). Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disorders, 15, 138–149. First citation in articleCrossref Medline, Google Scholar

  • Garcia-Amador, M., Merchán-Naranjo, J., Tapia, C., Moreno, C., Castro-Fornieles, J. & Baeza, I., et al. (2015). Neurological adverse effects of antipsychotics in children and adolescents. Journal of Clinical Psychopharmacology, 35, 686–693. First citation in articleCrossref Medline, Google Scholar

  • Gilbert, D. L. (2008). Drug-induced movement disorders in children. Annals of the New York Academy of Sciences, 1142, 72–84. First citation in articleCrossref Medline, Google Scholar

  • GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO): Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) (Hrsg.) (2015). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2015. Berlin: DIMDI, 2015. First citation in articleGoogle Scholar

  • Greenaway, M. & Elbe, D. (2009). Focus on aripiprazole: a review on its use in child and adolescent psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 18, 250–260. First citation in articleMedline, Google Scholar

  • Harten, P. N. van & Kahn, R. S. (1999). Tardive dystonia. Schizophrenia Bulletin, 25, 741–748. First citation in articleMedline, Google Scholar

  • Johnston, M. V. & Singer, H. S. (1982). Brain neurotransmitters and neuromodulators in pediatrics. Pediatrics, 70, 57–68. First citation in articleCrossref Medline, Google Scholar

  • Kumar, A., Datta, S. S., Wright, S. D., Furtado, V. A. & Russel, P. S. (2013). Atypical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic Reviews, October 15; 10:CD009582. DOI:10.1002/14651858.CD009582.pub2. First citation in articleGoogle Scholar

  • Lim, H.-K., Pae, C.-U., Lee, C. & Lee, C.-U. (2008). Tardive dystonic symptoms associated with aripiprazole treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 589–590. First citation in articleCrossref Medline, Google Scholar

  • Mankoski, R., Stockton, G., Manos, G., Marler, S., McQuade, R. & Forbes, R. A., et al. (2013). Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology, 23, 572–576. First citation in articleCrossref Medline, Google Scholar

  • Marsalek, M. (2000). Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry, 33(Suppl. 1), 14–33. First citation in articleMedline, Google Scholar

  • Matsuda, N., Hashimoto, N., Kusumi, I., Ito, K. & Koyama, T. (2012). Tardive laryngeal dystonia associated with aripiprazole monotherapy. Journal of Clinical Psychopharmacology, 32, 297–298. First citation in articleCrossref Medline, Google Scholar

  • Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I. & Roberts, E. A., et al. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30, 239–245. First citation in articleCrossref Medline, Google Scholar

  • Oh, G.H., Yu, J.-C., Choi, K.-S., Joo, E.-J. & Jeong, S.-H. (2015). Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in Schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investigation, 12, 46–54. First citation in articleCrossref Medline, Google Scholar

  • Ono, S., Suzuki, Y., Shindo, M., Endo, T., Fukui, N. & Sugai, T., et al. (2012). Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. Journal of Clinical Pharmacy and Therapeutics, 37, 370–372. First citation in articleCrossref Medline, Google Scholar

  • Oommen, E., Chand, P. K. & Sharma, P. S. V. N. (2006). Aripiprazole-induced tardive dystonia. Primary Care Companion to the Journal Clinical Psychiatry, 8, 378–379. First citation in articleGoogle Scholar

  • Pena, M. S., Yaltho, T. C. & Jankovic, J. (2011). Tardive dyskinesia and other movement disorders secondary to aripiprazole. Movement Disorders, 26, 147–152. First citation in articleMedline, Google Scholar

  • Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. & Stock, E., et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and Risperidone vs Placebo in patients with Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry, 60, 681–690. First citation in articleCrossref Medline, Google Scholar

  • Pringsheim, T. (2011). Missed diagnosis of tardive dystonia in an adolescent girl treated with risperidone. Journal of Child and Adolescent Psychopharmacology, 21, 191–194. First citation in articleCrossref Medline, Google Scholar

  • Pringsheim, T., Lam, D., Ching, H. & Patten, S. (2011). Metabolic and neurological complications of second-generation antipsychotic use in children. A systematic review and meta-analysis of randomized controlled trials. Drug Safety, 34, 651–668. First citation in articleCrossref Medline, Google Scholar

  • Pringsheim, T., Doja, A., Belanger, S. & Patten, S., CAMESA guideline group. (2011). Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics & Child Health, 16, 590–598. First citation in articleCrossref Medline, Google Scholar

  • Pringsheim, T., Panagiotopoulos, C., Davidson, J. & Ho, J., CAMESA guideline group. (2011). Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 20, 218–233. First citation in articleMedline, Google Scholar

  • Richardson, M. A., Haugland, G. & Craig, T. J. (1991). Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. American Journal of Psychiatry, 148, 1322–1328. First citation in articleMedline, Google Scholar

  • Roessner, V., Schoenefeld, K., Buse, J., Wanderer, S. & Rothenberger, A. (2012). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 40, 217–236. First citation in articleLink, Google Scholar

  • Ryu, S., Yoo, J. H., Kim, J. H., Choi, J. S., Baek, J. H. & Ha, K., et al. (2015). Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics. A cross-sectional and retrospective study. Journal of Clinical Psychopharmacology, 35, 13–21. First citation in articleCrossref Medline, Google Scholar

  • Sato, K., Yoshida, K. & Higushi, H. (2012). Probable aripiprazole-induced tardive writer’s cramp. Journal of Neuropsychiatry and Clinical Neuroscience, 24, . First citation in articleMedline, Google Scholar

  • Schooler, N. R. & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486–487. First citation in articleMedline, Google Scholar

  • Simpson, G. & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, Supplement 212, 11–19. First citation in articleCrossref, Google Scholar

  • Wolf, D. V. & Wagner, K. D. (1993). Tardive dyskinesia, tardive dystonia, and tardive tourette’s syndrome in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 3, 175–198. First citation in articleCrossref, Google Scholar

  • Wonodi, I., Reeves, G., Carmichael, D., Verovsky, I., Avila, M. T. & Elliott, A., et al. (2007). Tardive dyskinesia in children treated with atypical antipsychotic medications. Movement Disorders, 12, 1777–1782. First citation in articleCrossref Medline, Google Scholar

  • Woods, S. W., Martin, A., Spector, S. G. & McGlashan, T. H. (2002). Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1439–1446. First citation in articleCrossref Medline, Google Scholar